Tazobactum%2525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin-tazobactam is a combination extended-spectrum penicillin (ureidopenicillin) and a beta-lactamase inhibitor. It provides coverage against Gram-positive, Gram-negative (including *Pseudomonas aeruginosa*), and anaerobic pathogens. ## Primary Indications * Severe pneumonia (community or hospital-acquired) * Intra-abdominal infections (e.g., appendicitis, peritonitis) * Skin and skin-structure infections * Gynecologic infections (e.g., postpartum endometritis) * Febrile neutropenia (empiric therapy) ## Adult Dosing * **Standard dosing:** 3.375 g (3 g piperacillin/0.375 g tazobactam) IV every 6 hours. * **Severe infections:** 4.5 g (4 g piperacillin/0.5 g tazobactam) IV every 6 hours. * **Max dose:** 18 g piperacillin per day. * **Extended infusion:** For *Pseudomonas* or critically ill patients, 4.5 g infused over 4 hours every 8 hours may be utilized per institutional protocol. ## Pediatric Dosing * **General infection (≥ 9 months):** 100 mg piperacillin/12.5 mg tazobactam per kg up to 4 g piperacillin/0.5 g tazobactam every 8 hours. * **Febrile neutropenia:** 80 mg piperacillin/10 mg tazobactam per kg every 6 hours (Max: 4 g piperacillin/0.5 g tazobactam per dose). * *Note: Always verify pediatric dosing against local formulary/institutional guidelines as regimens vary significantly by age and weight.* ## Dose Adjustments * **Renal Impairment:** Requires dosage reduction for CrCl ≤ 40 mL/min. * CrCl 20–40 mL/min: 2.25 g to 3.375 g every 6–8 hours depending on severity. * CrCl < 20 mL/min: 2.25 g every 8–12 hours. * **Hepatic Impairment:** No dose adjustment required. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, or any beta-lactam (e.g., penicillins, cephalosporins). * History of anaphylaxis to any beta-lactam antibiotic. ## Adverse Effects * **Common:** Diarrhea, nausea, constipation, headache, insomnia. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (anaphylaxis), rash (including DRESS/SJS), leukopenia/neutropenia (with prolonged use), and seizures (primarily in renal failure). ## Key Drug Interactions * **Aminoglycosides:** May result in inactivation of aminoglycosides if mixed in the same IV line; administer at least 1 hour apart. * **Probenecid:** Increases serum half-life of piperacillin. * **Methotrexate:** May increase serum concentrations of methotrexate. * **Anticoagulants (Warfarin/Heparin):** May increase bleeding risk due to high-dose piperacillin affecting platelet aggregation. ## Monitoring * **Baseline:** Renal function (CrCl), baseline CBC with differential. * **Ongoing:** Monitor for signs of hypersensitivity, *C. difficile* symptoms (diarrhea), and electrolyte balance (high sodium content). * **Prolonged therapy (>10 days):** Weekly CBC for bone marrow suppression. ## Clinical Pearls * **Sodium Load:** Each 4.5 g dose contains approximately 11.2 mEq (258 mg) of sodium; consider in patients with heart failure or hypertension. * **No MRSA:** Piperacillin-tazobactam does not provide coverage for MRSA. * **Compatibility:** Highly unstable in many IV solutions; check specific Y-site compatibility charts. Always prioritize separate lines from aminoglycosides. *** **Educational Disclaimer:** This information is for educational purposes only and does not replace professional clinical judgment. Always verify current prescribing information, institutional guidelines, and drug database resources (e.g., Lexicomp, UpToDate) before administering medication.